Sonnet BioTherapeutic CVR

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Silexion Therapeutics

Micware

GCL Global

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Bristol-Myers Squibb Company

SONN.CVR

MBIO

IBBQ

LABU

SBIO

Creatv Bio, a cancer diagnostic blood testing company, announced one poster presentation and four poster abstracts for the 2026 ASCO Annual Meeting, scheduled for May 29-June 2, 2026, in Chicago. The presentations include studies on blood-based biomarkers for predicting progression-free survival in metastatic breast cancer and the use of the LifeTracDx® blood test in collaboration with pharmaceutical partners. The company aims to develop diagnostic tools for cancer therapies and provide continuous monitoring for optimizing treatment regimens.

MorningStar

Mustang Bio

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

BriaCell Therapeutics

BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM)

BRIACELL THERAPEUTICS CORP C/WTS 26/02/2026(TO PUR COM)

CytoDyn Inc.

BRIACELL THERAPEUTICS CORP C/WTS 15/01/2031 (TO PUR  COM)

Creatv Announces Five Clinical Data Presentations at ASCO 2026

01276

600276

Hengrui Pharma and Braveheart Bio announced positive results from a Phase 2 study of HRS-1893 for obstructive hypertrophic cardiomyopathy (oHCM). The study showed significant reductions in left ventricular outflow tract gradient (LVOT-G) with minimal changes in left ventricular ejection fraction (LVEF). The treatment demonstrated a rapid onset of effect, with 89% of patients responding well to a 40 mg or 60 mg twice-daily regimen. The results support further clinical development, with plans for a global pivotal study in 2026. The treatment was well tolerated with no new safety concerns identified.

prnewswire

HENGRUI PHARMA

Hengrui Pharma

CS精准医

Harvard Bioscience

Ping An CSI Medicine and Medical Device Innovation ETF

SPDR S&P Health Equip

Guotai CSI Bio-medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Kraneshares MSCI All China H

ICBCCS SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Tianhong CNI BIOMEDICINE ETF

Invesco Biotechnology & Genome ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng Health Care ETF(QDII)

iShares US Medical Devices

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

09:35 ETHengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy

The company has promoted Marc Evanchik to the position of Chief Scientific Officer to oversee clinical development, research, and scientific strategy. Concurrently, Brittany de Temple has joined as the Senior Vice President of Development Operations to enhance preparedness for expanded clinical operations. These key appointments come amidst the company's progress towards the upcoming launch of global initiatives.

Unusual Whales

Braveheart Bio appoints Marc Evanchik as CSO and Brittany de Temple as SVP, advancing towards global Phase 3 trials.

Sonnet BioTherapeutic CVR(SONN.CVR.US)

Creatv Announces Five Clinical Data Presentations at ASCO 2026

09:35 ETHengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy

Braveheart Bio appoints Marc Evanchik as CSO and Brittany de Temple as SVP, advancing towards global Phase 3 trials.